{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:25:57Z","timestamp":1773296757390,"version":"3.50.1"},"reference-count":47,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.3892\/ijo.2012.1463","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T10:27:41Z","timestamp":1336472861000},"page":"639-651","source":"Crossref","is-referenced-by-count":10,"title":["Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab"],"prefix":"10.3892","volume":"41","author":[{"given":"LEOPOLDO L.","family":"LUISTRO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAMES A.","family":"ROSINSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HONGJIN","family":"BIAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SUBAL","family":"BISHAYEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PRANELA","family":"RAMESHWAR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NICHOLAS M.","family":"PONZIO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEVE R.","family":"RITLAND","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,5,8]]},"reference":[{"key":"key20180107184807_b1-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-5793(97)00412-2","article-title":"The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions","volume":"410","author":"Alroy","year":"1997","journal-title":"FEBS Lett"},{"key":"key20180107184807_b2-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"key20180107184807_b3-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancers","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"key20180107184807_b4-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"key20180107184807_b5-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b6-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b7-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"key20180107184807_b8-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"key20180107184807_b9-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b10-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107184807_b11-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b12-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"key20180107184807_b13-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107184807_b14-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"key20180107184807_b15-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1200\/JCO.2009.22.1507","article-title":"Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer","volume":"27","author":"Spector","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b16-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/jnci\/93.24.1830","article-title":"Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect","volume":"93","author":"Albanell","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"key20180107184807_b17-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1158\/0008-5472.CAN-03-3900","article-title":"p27Kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"key20180107184807_b18-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"key20180107184807_b19-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107184807_b20-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1038\/onc.2010.365","article-title":"The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells","volume":"29","author":"Dhillon","year":"2010","journal-title":"Oncogene"},{"key":"key20180107184807_b21-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nm.2309","article-title":"Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways","volume":"17","author":"Zhang","year":"2011","journal-title":"Nat Med"},{"key":"key20180107184807_b22-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1074\/jbc.M005599200","article-title":"Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII\/DeltaEGFR) expressed in cancer cells","volume":"276","author":"Fernandes","year":"2001","journal-title":"J Biol Chem"},{"key":"key20180107184807_b23-ijo-41-02-0639","first-page":"361","article-title":"Expression profile of tyrosine kinases in breast cancer","volume":"8","author":"Meric","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20180107184807_b24-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/bcr317","article-title":"Characterization of adjacent breast tumors using oligonucleotide microarrays","volume":"3","author":"Unger","year":"2001","journal-title":"Breast Cancer Res"},{"key":"key20180107184807_b25-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-4-56","article-title":"Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia","volume":"4","author":"Raponi","year":"2004","journal-title":"BMC Cancer"},{"issue":"Suppl","key":"key20180107184807_b26-ijo-41-02-0639","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski","year":"1999","journal-title":"Semin Oncol"},{"key":"key20180107184807_b27-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1074\/jbc.M011248200","article-title":"Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland","volume":"276","author":"Schroeder","year":"2001","journal-title":"J Biol Chem"},{"key":"key20180107184807_b28-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ctrv.2008.09.003","article-title":"HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors","volume":"35","author":"Nielsen","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"key20180107184807_b29-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-05-1109","article-title":"Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts","volume":"12","author":"du Manoir","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107184807_b30-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-009-0412-3","article-title":"MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells","volume":"118","author":"Fessler","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107184807_b31-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10549-010-1281-5","article-title":"HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib","volume":"130","author":"Valabrega","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107184807_b32-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1081\/CNV-200039645","article-title":"Low overexpression of HER-2\/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy","volume":"22","author":"Ramanathan","year":"2004","journal-title":"A phase II trial Cancer Invest"},{"key":"key20180107184807_b33-ijo-41-02-0639","first-page":"1829","article-title":"Antibody to HER-2\/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cells","volume":"9","author":"Pietras","year":"1994","journal-title":"Oncogene"},{"key":"key20180107184807_b34-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5414\/CPP42642","article-title":"Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model","volume":"42","author":"Ritter","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key20180107184807_b35-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O\u2019Brien","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20180107184807_b36-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107184807_b37-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b38-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1158\/0008-5472.CAN-09-0834","article-title":"Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high\/CD24low\/HER2low breast cancer stem cells","volume":"69","author":"Reim","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107184807_b39-ijo-41-02-0639","first-page":"1119","article-title":"Expression of the cell surface mucin gene family in adenocarcinomas","volume":"25","author":"Packer","year":"2004","journal-title":"Int J Oncol"},{"key":"key20180107184807_b40-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/104454901750232463","article-title":"Regulation of MUC1 expression in human mammary cell lines by the c-ErbB2 and ras signaling pathways","volume":"20","author":"Scibetta","year":"2001","journal-title":"DNA Cell Biol"},{"key":"key20180107184807_b41-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180107184807_b42-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1074\/jbc.C000754200","article-title":"The c-Src tyrosine kinase regulates signaling of the human DF3\/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin","volume":"276","author":"Li","year":"2001","journal-title":"J Biol Chem"},{"key":"key20180107184807_b43-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"key20180107184807_b44-ijo-41-02-0639","first-page":"viii97","article-title":"A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (TDM-1) in patients (PTS) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy [abstract 2770]","volume":"21","author":"Krop","year":"2010","journal-title":"Ann Oncol"},{"key":"key20180107184807_b45-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107184807_b46-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107184807_b47-ijo-41-02-0639","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2012.1463\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T15:03:00Z","timestamp":1687446180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2012.1463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,8]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,5,8]]},"published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.3892\/ijo.2012.1463"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2012.1463","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,8]]}}}